DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns negative
Q1 FY2026 Accumulated OCI was -$26K, compared with $5K a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -620.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 50K USD
- Year-over-year change
- +117.4%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50K | +117.4% |
| FY2024 | 2024-12-31 | 23K | +283.3% |
| FY2023 | 2023-12-31 | 6K | +108.1% |
| FY2022 | 2022-12-31 | (74K) | -45.1% |
| FY2021 | 2021-12-31 | (51K) | — |
Accumulated OCI vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 Accumulated OCI of -$26K is the 4th highest of the 7 companies compared; the peer median is -$23.5K.
- Its year-over-year change of -620.0% is the lowest of 5, against a peer median of -121.5%.
- Accumulated OCI amounts to 0.0% of total assets for DMAC, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BIOABioAge Labs, Inc. | Mar 2026 | $73K | -72.3% | +18.5% | 0.0% |
| Mar 2026 | $6K | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $6K | — | — | 0.0% | |
| Mar 2026 | -$26K | -620.0% | — | 0.0% | |
| Mar 2026 | -$53K | -170.7% | — | 0.0% | |
| Mar 2026 | -$135K | — | — | 0.0% | |
| Jun 2026 | -$1.97M | -309.7% | — | 0.2% | |
| Peer median (excluding DMAC) | -$23.5K | -121.5% | +9.3% | 0.0% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.